Zacks Investment Research upgraded shares of PALATIN TECH (PTN) from NEUTRAL to OUTPERFORM on November 22, 2012, with a target price of $0.70.
Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PALATIN TECH (PTN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment